MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Bradykinesia"

  • 2022 International Congress

    Comparison between clinical and kinematic assessment of bradykinesia

    G. Paparella, A. de Biase, L. Angelini, A. Cannavacciuolo, D. Colella, A. Guerra, D. Alunni Fegatelli, A. Berardelli, M. Bologna (Pozzilli, Italy)

    Objective: To compare the clinical and kinematic assessment of bradykinesia (movement slowness). Background: Bradykinesia may be present not only in Parkinson’s disease (PD), but also…
  • 2022 International Congress

    A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis

    M. Shah, L. Patil, M. Bhatt (Mumbai, India)

    Objective: To report the clinical course of secondary parkinsonism due to methanol toxicity with good levodopa responsiveness in the background of COVID-19 crisis. Background: The…
  • 2022 International Congress

    Frequency dependent interindividual variability of the deep brain stimulation effect on upper-limb bradykinesia

    P. Dorin, D. Brogle, S. Hägele-Link, M. Krüger, G. Kägi, F. Brugger (St. Gallen, Switzerland)

    Objective: To demonstrate that there are interindividual differences in the response of upper limb bradykinesia to subthalamic deep brain stimulation (STN-DBS) in patients with Parkinson’s…
  • 2022 International Congress

    High-beta Oscillations Predict Outcome of Subthalamic Deep Brain Stimulation in Parkinson’s Disease

    P-L. Chen, Y-C. Chen, P-H. Tu, T-C. Liu, H-T. Wu, M-C. Yeap, C-H. Yeh, C-S. Lu, C-C. Chen (Taoyuan City, Taiwan)

    Objective: We evaluated whether low-β and high-β band activity recorded from the subthalamic nucleus (STN) region predicts efficacy of deep brain stimulation (DBS) in Parkinson's…
  • 2022 International Congress

    Overnight stimulation: a new rescue strategy for deep brain stimulation-induced bradykinesia in dystonia?

    N. Pozzi, T. Binder, F. Avantaggiato, I. Isaias, J. Volkmann, P. Capetian (Wuerzburg, Germany)

    Objective: We report the serendipity case of overnight stimulation for the management of stimulation-induced bradykinesia in two patients with generalized dystonia and clinically-effective pallidal deep…
  • 2022 International Congress

    Validation of the PD Home Diary for Assessment of Motor Fluctuations in Advanced Parkinson’s Disease

    M. Löhle, A. Bremer, F. Gandor, J. Timpka, P. Odin, G. Ebersbach, A. Storch (Rostock, Germany)

    Objective: To determine the validity of the Parkinson’s disease (PD) home diary for quantification of motor states in patients with advanced PD and motor fluctuations.…
  • 2022 International Congress

    TREMOR AND BRADYKINESIA ARE TWO UNRELATED SIDE EFFECTS INDUCED BY VALPROATE INTAKE

    A. de Biase, G. Paparella, L. Angelini, A. Cannavacciuolo, D. Colella, E. Cerulli Irelli, A. Gialllonardo, C. Di Bonaventura, A. Berardelli, M. Bologna (Rome, Italy)

    Objective: To better characterize clinical and neurophysiological features of valproate-induced tremor in patients with epilepsy and the effect of valproate on the execution of voluntary…
  • 2022 International Congress

    Anatomical Substrates for Motor Subcomponents of Bradykinesia in Parkinson’s Disease after Subthalamic Nucleus Deep Brain Simulation

    MJ. Kim, Y. Shi, Y. Salimpour, WS. Anderson, K. Mills (Baltimore, USA)

    Objective: To evaluate distinct anatomical substrates modulating motor subcomponents of bradykinesia following Subthalamic Nucleus (STN) Deep Brain Stimulation (DBS) in Parkinson’s Disease (PD). Background: PD…
  • 2022 International Congress

    Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2

    K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, M. Scelsi, L. Essioux, A. Monnet, B. van Lier, H. Svoboda, T. Kustermann, W. Zago, T. Nikolcheva, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

    Objective: To determine whether the positive effects of prasinezumab on motor progression measured by Roche PD Mobile Application (PASADENA study Part 1; 0-52 weeks; NCT03100149)…
  • 2022 International Congress

    EFFECTS OF OPICAPONE IN PARKINSON DISEASE AS ASSESSED BY KINEMATIC TECHNIQUES

    D. Colella, A. de Biase, A. Cannavacciuolo, L. Angelini, A. Guerra, G. Paparella, A. Berardelli, G. Fabbrini, M. Bologna (Rome, Italy)

    Objective: We aimed to objectively investigate the effects of Opicapone on bradykinesia in Parkinson's Disease (PD) by kinematic analysis. Background: By increasing L-dopa bioavailability, catechol-O-methyl…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 27
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley